Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

141. Diarrhoea in Adult Cancer Patients: ESMO Clinical Practice Guidelines

Diarrhoea in Adult Cancer Patients: ESMO Clinical Practice Guidelines CLINICAL PRACTICE GUIDELINES Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines † P. Bossi 1 , A. Antonuzzo 2 , N. I. Cherny 3 , O. Rosengarten 3 , S. Pernot 4 , F. Trippa 5 , U. Schuler 6 , A. Snegovoy 7 , K. Jordan 8 & C. I. Ripamonti 9 , on behalf of the ESMO Guidelines Committee * 1 Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; 2 U.O. Oncologia Medica (...) ; 7 N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; 8 Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany; 9 Oncology-Supportive Care in Cancer Unit, Department Onco-Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy *Correspondence to: ESMO Guidelines Committee, ESMO Head Of?ce, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee

European Society for Medical Oncology2018

142. Delirium in Adult Cancer Patients: ESMO Clinical Practice Guidelines

Delirium in Adult Cancer Patients: ESMO Clinical Practice Guidelines CLINICAL PRACTICE GUIDELINES Delirium in adult cancer patients: ESMO Clinical Practice Guidelines † S. H. Bush 1,2,3,4 , P. G. Lawlor 1,2,3,4 , K. Ryan 5,6,7 , C. Centeno 8,9,10 , M. Lucchesi 11 , S. Kanji 2,12 , N. Siddiqi 13,14 , A. Morandi 15 , D. H. J. Davis 16 , M. Laurent 17,18 , N. Schofield 19 , E. Barallat 20 & C. I. Ripamonti 21 , on behalf of the ESMO Guidelines Committee * 1 Division of Palliative Care, Department (...) IRCCS, Istituto Nazionale dei Tumori, Milano, Italy *Correspondence to: ESMO Guidelines Committee, ESMO Head Of?ce, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: April 2018. Delirium is a neurocognitive syndrome that commonly occurs in older populations and people with cancer, particularly in those with advanced disease and in the last hours or days of life. While an underlying malignancy and its complications predispose

European Society for Medical Oncology2018

143. Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.

Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. BACKGROUND: Minimally invasive surgery was adopted as an alternative to laparotomy (open surgery) for radical hysterectomy in patients with early-stage cervical cancer before high-quality evidence regarding its effect on survival was available. We sought to determine the effect of minimally invasive surgery on all-cause mortality among women undergoing radical hysterectomy for cervical cancer. METHODS: We (...) performed a cohort study involving women who underwent radical hysterectomy for stage IA2 or IB1 cervical cancer during the 2010-2013 period at Commission on Cancer-accredited hospitals in the United States. The study used inverse probability of treatment propensity-score weighting. We also conducted an interrupted time-series analysis involving women who underwent radical hysterectomy for cervical cancer during the 2000-2010 period, using the Surveillance, Epidemiology, and End Results program database

NEJM2018

144. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.

Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. BACKGROUND: There are limited data from retrospective studies regarding whether survival outcomes after laparoscopic or robot-assisted radical hysterectomy (minimally invasive surgery) are equivalent to those after open abdominal radical hysterectomy (open surgery) among women with early-stage cervical cancer. METHODS: In this trial involving patients with stage IA1 (lymphovascular invasion), IA2, or IB1 cervical (...) cancer and a histologic subtype of squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, we randomly assigned patients to undergo minimally invasive surgery or open surgery. The primary outcome was the rate of disease-free survival at 4.5 years, with noninferiority claimed if the lower boundary of the two-sided 95% confidence interval of the between-group difference (minimally invasive surgery minus open surgery) was greater than -7.2 percentage points (i.e., closer to zero). RESULTS

NEJM2018

145. Laparoscopy versus laparotomy for the management of early stage endometrial cancer.

Laparoscopy versus laparotomy for the management of early stage endometrial cancer. BACKGROUND: This is an update of a previous Cochrane Review published in 2012, Issue 9.Surgery for endometrial cancer (hysterectomy with removal of both fallopian tubes and ovaries) is performed through laparotomy. It has been suggested that the laparoscopic approach is associated with a reduction in operative morbidity. Over the last two decades there has been a steady increase of the use of laparoscopy (...) for endometrial cancer. This review investigated the evidence of benefits and harms of laparoscopic surgery compared with laparotomy for presumed early stage endometrial cancer. OBJECTIVES: To compare overall survival (OS) and disease free survival (DFS) for laparoscopic surgery versus laparotomy in women with presumed early stage endometrial cancer. SEARCH METHODS: For this update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 5) in the Cochrane Library, MEDLINE via

Cochrane2018

146. An assessment of prognostic immunity markers in breast cancer

An assessment of prognostic immunity markers in breast cancer 30393759 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer An assessment of prognostic immunity markers in breast cancer. 35 10.1038/s41523-018-0088-0 Tumor-infiltrating lymphocytes (TIL) and immunity gene signatures have been reported to be significantly prognostic in breast cancer but have not yet been applied for calculation of risk of recurrence in clinical assays. A compact set of 17 immunity genes was derived (...) herein from an Affymetrix-derived gene expression dataset including 1951 patients (AFFY1951). The 17 immunity genes demonstrated significant prognostic stratification of estrogen receptor (ER)-negative breast cancer patients with high proliferation gene expression. Further analysis of blood and breast cancer single-cell RNA-seq datasets revealed that the 17 immunity genes were derived from TIL that were inactive in the blood and became active in tumor tissue. Expression of the 17 immunity genes

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

147. Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study

Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study 30417053 2018 12 07 2352-3727 4 4 2018 Oct 29 Bladder cancer (Amsterdam, Netherlands) Bladder Cancer Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study. 419-428 10.3233/BLC-180184 Chemotherapy and major pelvic surgery are established risk factors for venous thromboembolism (VTE). We evaluate the incidence rate (...) , timing, and factors associated with VTE in patients with bladder cancer who underwent radical cystectomy and peri-operative chemotherapy in routine clinical practice. Electronic records of treatment were linked to the population-based Ontario Cancer Registry to identify all patients who underwent cystectomy for bladder cancer in Ontario 1994-2013. VTE events within 6 months of before or after cystectomy were identified using diagnostic codes recorded on hospital admissions and emergency department

Bladder cancer (Amsterdam, Netherlands)2018 Full Text: Link to full Text with Trip Pro

148. Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer

Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer 30417052 2018 12 07 2352-3727 4 4 2018 Oct 29 Bladder cancer (Amsterdam, Netherlands) Bladder Cancer Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer. 411-418 10.3233/BLC-180188 Baseline sarcopenia or severe lean muscle deficiency is independently associated with increased mortality (...) after cystectomy for muscle-invasive urothelial carcinoma of the bladder (MIUC). The impact of chemotherapy on muscle mass in MIUC patients remains undefined. To describe preoperative changes in body composition in MIUC patients receiving platinum-based neoadjuvant chemotherapy (NC). Patients with cT2-4 N0-1 M0 UC of the bladder who received NC were identified. Lumbar skeletal muscle index (SMI, cm 2 /m 2 ), visceral adipose index (VAI, cm 2 /m 2 ), and the subcutaneous and intramuscular adipose

Bladder cancer (Amsterdam, Netherlands)2018 Full Text: Link to full Text with Trip Pro

149. Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer

Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer 30417054 2018 12 07 2352-3727 4 4 2018 Oct 29 Bladder cancer (Amsterdam, Netherlands) Bladder Cancer Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer. 429-440 10.3233/BLC-180175 The Fourth Annual Albert Institute Bladder Cancer Care and Research Symposium was held from September 14th-16th in Houston, Texas. The symposium covered a range of topics relevant (...) to bladder cancer, including basic science aspects of immunology and immunotherapy that inform clinical management; intravesical therapy for non-muscle invasive disease; understanding the nuances of carcinoma in situ ; and optimizing patient care and outcomes following therapy. The moving landscape of bladder cancer from an industry perspective was also discussed. In the following sections we discuss intrinsic and extrinsic factors, including the immune microenvironment and sex bias, in the context

Bladder cancer (Amsterdam, Netherlands)2018 Full Text: Link to full Text with Trip Pro

150. Perioperative Blood Transfusions and Bladder Cancer Outcomes

Perioperative Blood Transfusions and Bladder Cancer Outcomes 30417056 2018 12 07 2352-3727 4 4 2018 Oct 29 Bladder cancer (Amsterdam, Netherlands) Bladder Cancer Perioperative Blood Transfusions and Bladder Cancer Outcomes. 445-446 10.3233/BLC-189039 Messing Edward M EM University of Rochester Medical Center, Rochester, NY, USA. eng Journal Article 2018 10 29 Netherlands Bladder Cancer 101668567 2018 11 13 6 0 2018 11 13 6 0 2018 11 13 6 1 epublish 30417056 10.3233/BLC-189039 BLC189039

Bladder cancer (Amsterdam, Netherlands)2018 Full Text: Link to full Text with Trip Pro

151. Challenging Cases in Urothelial Cancer

Challenging Cases in Urothelial Cancer 30417055 2018 11 12 2352-3727 4 4 2018 Oct 29 Bladder cancer (Amsterdam, Netherlands) Bladder Cancer Challenging Cases in Urothelial Cancer. 441-444 10.3233/BLC-189038 Soloway Mark S MS Urologic Oncology, Memorial Physician Group, Division of Urology, Memorial Healthcare System, Aventura, FL, USA. eng Journal Article 2018 10 29 Netherlands Bladder Cancer 101668567 2018 11 13 6 0 2018 11 13 6 0 2018 11 13 6 1 epublish 30417055 10.3233/BLC-189038 BLC189038

Bladder cancer (Amsterdam, Netherlands)2018 Full Text: Link to full Text with Trip Pro

152. Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients 30417050 2018 12 07 2352-3727 4 4 2018 Oct 29 Bladder cancer (Amsterdam, Netherlands) Bladder Cancer Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients. 395-401 10.3233/BLC-180191 Adjuvant intravesical instillations with bacillus Calmette-Guérin (BCG) is the recommended treatment option for patients with intermediate-and high-risk non (...) -muscle invasive bladder cancer (NMIBC). Despite adequate BCG treatment, a large proportion of patients experience a recurrence. Although radical cystectomy is the gold standard for BCG unresponsive NMIBC, some patients are unfit or unwilling to consider this option. To assess the effectiveness of Hyperthermic IntraVEsical Chemotherapy (HIVEC ® ) in BCG unresponsive NMIBC patients. A post-hoc analysis was conducted of prospectively included intermediate-and high-risk NMIBC patients who were planned

Bladder cancer (Amsterdam, Netherlands)2018 Full Text: Link to full Text with Trip Pro

153. Extended-field radiotherapy for locally advanced cervical cancer.

Extended-field radiotherapy for locally advanced cervical cancer. BACKGROUND: The para-aortic lymph nodes (located along the major vessels in the mid and upper abdomen) are a common place for disease recurrence after treatment for locally advanced cervical cancer. The para-aortic area is not covered by standard pelvic radiotherapy fields and so treatment to the pelvis alone is inadequate for women at a high risk of occult cancer within para-aortic lymph nodes. Extended-field radiotherapy (RT (...) ) widens the pelvic RT field to include the para-aortic lymph node area. Extended-field RT may improve outcomes in women with locally advanced cervical cancer by treating occult disease in para-aortic nodes not identified at pretreatment imaging. However, RT treatment of the para-aortic area can cause severe adverse effects, so may increase harms.Studies of pelvic chemoradiotherapy (CRT) demonstrated improved survival rates compared to pelvic RT alone. CRT is now the standard of care in the treatment

Cochrane2018

154. Prognostic Nutritional Index: an easy nutritional screening for patients with head and neck cancer?

Prognostic Nutritional Index: an easy nutritional screening for patients with head and neck cancer? 30426972 2018 12 07 2059-7029 3 6 2018 ESMO open ESMO Open Prognostic Nutritional Index: an easy nutritional screening for patients with head and neck cancer? e000449 10.1136/esmoopen-2018-000449 Bossi Paolo P Head and Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. eng Journal Article 2018 10 24 England ESMO Open 101690685 2059-7029 nutrition (...) prognostic markers Competing interests: None declared. 2018 09 28 2018 09 29 2018 11 15 6 0 2018 11 15 6 0 2018 11 15 6 1 epublish 30426972 10.1136/esmoopen-2018-000449 esmoopen-2018-000449 PMC6212675 Acta Otolaryngol. 2017 Jul;137(7):778-785 28125312 Anticancer Res. 2017 Jul;37(7):3781-3786 28668874 Eur J Cancer. 2018 Mar;92:69-76 29428866 Cancer. 1999 Aug 1;86(3):519-27 10430262 Clin Nutr. 2017 Dec;36(6):1681-1685 27847115 Clin Nutr. 2014 Apr;33(2):204-10 23849811 Clin Nutr. 2013 Oct;32(5):671-8

ESMO open2018 Full Text: Link to full Text with Trip Pro

155. Risk factors for the development of brain metastases in patients with HER2-positive breast cancer

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer 30425844 2018 12 07 2059-7029 3 6 2018 ESMO open ESMO Open Risk factors for the development of brain metastases in patients with HER2-positive breast cancer. e000440 10.1136/esmoopen-2018-000440 Patients with metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) frequently experience brain metastases (BM). We aimed to define risk factors for the development of BM (...) in patients with HER2+ BC and to report on their outcome. This is a retrospective analysis of patients diagnosed with HER2+ BC between January 2000 and December 2014 at Institut Jules Bordet, Belgium. Statistical analyses were conducted with SAS V.9.4 using Kaplan-Meier method and Cox regression analyses. A total of 483 patients were included of whom 108 (22.4%) developed metastases and 52 (10.8%) BM. Among 96 metastatic patients without BM at diagnosis, 40 (41.7%) developed BM in the course

ESMO open2018 Full Text: Link to full Text with Trip Pro

156. Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer 30426973 2018 12 07 2059-7029 3 6 2018 ESMO open ESMO Open Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer. e000425 10.1136/esmoopen-2018-000425 Locally advanced head and neck squamous cell carcinoma (LAHNSCC) is a heterogeneous disease in which better predictive and prognostic factors (...) cohort of 50 patients. Receiver operating characteristic curve analysis was used to establish optimal cut-off. Univariate and multivariate analyses of prognostic factors for overall survival (OS) were performed. Independent predictors of OS identified in multivariate analysis were confirmed in a validation cohort of 95 patients. In the univariate analysis, low PNI (PNI<45) (p=0.001), large primary tumour (T4) (p=0.044) and advanced lymph node disease (N2b-N3) (p=0.025) were significantly associated

ESMO open2018 Full Text: Link to full Text with Trip Pro

157. Dose escalation for locally advanced pancreatic cancer: How high can we go?

Dose escalation for locally advanced pancreatic cancer: How high can we go? 30370371 2018 11 14 2452-1094 3 4 2018 Oct-Dec Advances in radiation oncology Adv Radiat Oncol Dose escalation for locally advanced pancreatic cancer: How high can we go? 693-700 10.1016/j.adro.2018.07.008 There are limited treatment options for locally advanced, unresectable pancreatic cancer (LAPC) and no likelihood of cure without surgery. Radiation offers an option for local control, but radiation dose has (...) ) constraints were achieved for 90% of generated plans: Duodenum V20 < 30 cc, V30 < 3 cc, V35 < 1 cc; Small Bowel V20 < 15 cc, V30 < 1 cc, V35 < 0.1 cc; Stomach V20 < 20 cc, V30 < 2 cc, V35 < 1 cc. V40 < 0.5 cc was achieved for all OAR. Dose escalation to 60 Gy is dosimetrically feasible with adequate GTV coverage. The identified constraints for OAR's will be used in ongoing clinical trials. Colbert Lauren E LE Department of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas

Advances in radiation oncology2018 Full Text: Link to full Text with Trip Pro

158. Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE

Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE 30430023 2018 11 15 2059-7029 3 6 2018 ESMO open ESMO Open Report from the ESMO 2018 presidential symposium-Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE. e000451 10.1136/esmoopen-2018-000451 Parker Chris C The Royal Marsden NHS Foundation Trust (...) , Sutton, UK. The Institute of Cancer Research, Sutton, UK. eng Journal Article 2018 10 21 England ESMO Open 101690685 2059-7029 podcast Competing interests: None declared. 2018 10 04 2018 10 04 2018 11 16 6 0 2018 11 16 6 0 2018 11 16 6 1 epublish 30430023 10.1136/esmoopen-2018-000451 esmoopen-2018-000451 PMC6215689

ESMO open2018 Full Text: Link to full Text with Trip Pro

159. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. BACKGROUND: Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib in relapsed disease has been well established, but the benefit of olaparib as maintenance therapy in newly diagnosed disease is uncertain. METHODS: We conducted (...) an international, randomized, double-blind, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy in patients with newly diagnosed advanced (International Federation of Gynecology and Obstetrics stage III or IV) high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer (or a combination thereof) with a mutation in BRCA1, BRCA2, or both ( BRCA1/2) who had a complete or partial clinical response after platinum-based chemotherapy. The patients were

NEJM2018

160. ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer

ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer 30425847 2018 11 14 2059-7029 3 6 2018 ESMO open ESMO Open ESMO 2018 presidential symposium-IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer. e000453 10.1136/esmoopen-2018-000453 Schmid Peter P Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, England. eng Journal Article 2018 10 20 England ESMO Open

ESMO open2018 Full Text: Link to full Text with Trip Pro